Bingnan Zhang, MD
Hospitalist · Houston, TXNPI 1508284142
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,897 of the $2,949 with a category attached, or 64.3%. Daiichi Sankyo Inc. accounts for 90.8% of it on its own, with 2 other manufacturers making up the rest. Among hospitalist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 9 payments — averaging $327.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$3K
- Lilly USA, LLC$247
- Nuvation Bio Inc.$23
Across 3 payments — averaging $173,551 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$521K
What the payments were for
- Consulting fees$1,89764%
- Travel & lodging$78227%
- Food & beverage$231%
- Education$2478%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 5 | $2,679 |
| Lilly USA, LLC | 3 | $247 |
| Nuvation Bio Inc. | 1 | $23 |
How this compares
$2,949 in reported general payments places this provider in the 95th percentile of 1,284 hospitalist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 70 | $1,174,766 |
| EliquisApixaban | 12 | $8,357 |
| Dexamethasone | 22 | $309 |
| Ondansetron Hcl | 30 | $206 |
| Gabapentin | 11 | $63 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in Houston
- Ryan NealHouston$154K
- Ahmad BaroutHouston$44K
- Laxman KalvakuntlaHouston$30K
- Joshua HahnHouston$23K
- Grace OdiHouston$14K
- Spencer SuHouston$9K
- Martin Chacon PortilloHouston$9K
- Abeer SiddiqiHouston$9K
- Brent GudenkaufHouston$8K
- Dilpreet SinghHouston$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.